Press Releases
Date picker
Category
Results per page
Kancera announces results from the ROR project in connection with a presentation on November 17th
In connection with a presentation at the Swedish Shareholders' Association on 17 November in Vimmerby, Kancera communicates new results in the ROR project. These results indicate that the company's ROR…
Kancera prepares for clinical development
Kancera AB (publ) announced today that Niclas Brynne has been appointed to lead Kancera's clinical development projects. He will be part of the management team and report directly to the…
Interim Report for Kancera AB (publ) Q2 2016 January 1 – June 30, 2016
Regulatory
As a consequence of the acquisition of the subsidiary Kancera Förvaltning AB on 2016-06-16, the present Interim Report, Q2 2016, is prepared in accordance with IAS 34 and related parts…
Kancera provides operational update of the Fractalkine and ROR projects
Kancera reports that the Fractalkine antagonist KAN0440567 is able to eliminate pain resulting from inflammation of the pancreas and that the ROR inhibitor KAN0439834 has been shown to effectively kill…
Interim Report for Kancera AB (publ) Q1 2016, January 1 – March 31, 2016
Regulatory
The period January to March 2016 in brief R&D expenses for the period amounted to SEK 4.2m (SEK 4.2m). Operating income for the period amounted to SEK -5.1m (SEK 4.9m).…
Kancera acquires the Fractalkine project
Due to positive efficacy data in disease models of cancer and pain, Kancera's Board of Directors has decided to exercise the exclusive option to acquire the Fractalkine project.
Kancera provides operational update of the ROR and PFKFB3 projects
Kancera reports that ROR inhibitors have been tested against human triple negative breast cancer transferred to zebrafish. The experiments showed that Kancera's small molecule ROR inhibitors are able to both…
Kancera provides operational update of the ROR and Fractalkine projects
Kancera reported that the company has developed a new series of ROR inhibitors that show improved pharmaceutical properties which will allow preclinical studies of their effect on e.g. solid tumors.…
Interim Report for Kancera AB (publ) Q4 2015, January 1 – December 31, 2015
Regulatory
The period January to December 2015 and the fourth quarter 2015 in brief R&D expenses for the period amounted to SEK 20.4m (SEK 13.7m) of which the fourth quarter constituted…
Kancera provides operational update of the small molecule patent portfolio
Kancera's patent covering small molecule inhibitors of PFKFB3 has been approved in the United States. Further, a patent application covering new chemical series in the HDAC6 project has been filed…